liver dialysis


Also found in: Wikipedia.

liver dialysis

Therapeutics The use of hepatocytes either in cartridges, as in an bioartificial liver or via cross-perfusion with other organisms, either human or animal origin to provide metabolic support for a Pt in acute hepatic failure. See Artificial liver.
Mentioned in ?
References in periodicals archive ?
Recent treatments using CytoSorb in liver failure patients have confirmed previous reports of equivalent or superior removal of hepatic toxins from blood, compared with existing liver dialysis therapies.
Contract award: disposable delivery kits liver dialysis lease with the camera and the delivery of fluids and renal dialysis kits with cameras for spwsz lease in szczecin.
McCready shares with us a description of the role of albumin dialysis in liver failure, the potential adverse effects of this therapy, and the impact of liver dialysis on the nursing care of this patient population.
Speakers include topics on generational differences in the workplace, as well as liver dialysis.
The ELAD functions as a liver dialysis system that augments the metabolic functions of a patient's liver, thereby enabling a bridge to transplant or liver recovery.
Gambro AB develops, manufactures and supplies products and therapies for kidney and liver dialysis, myeloma kidney therapy and other extracorporeal therapies for chronic and acute patients.
Vital Therapies" or the "Company") (NASDAQ: VTL) plunged yesterday on a report that the Company has misled investors regarding the Phase 2 VTI-206 study of its Extracorporeal Liver Assist Device ("ELAD"), a biological liver dialysis technology.
This article includes an overview of liver failure and a description of the role of albumin dialysis in liver failure, the potential adverse effects of this therapy, and the impact of liver dialysis on the nursing care of this patient population.
Contract notice: Disposable delivery kits liver dialysis lease with the camera and the delivery of fluids and renal dialysis kits with cameras for spwsz lease in szczecin.
Despite the use of the anti-viral therapy acyclovir, and despite the use of traditional liver dialysis therapy (MARS), the patient continued to deteriorate, requiring increasing circulatory support with vasopressors, and developed a massive inflammatory response with an IL-6 cytokine concentration of ~81,000 pg/mL, far above normal (<10 pg/mL) and well above what is commonly seen in sepsis.
market for selective plasma filtration products is estimated to be $900 million, and could be significantly higher if additional medical conditions such as septic shock are found to benefit from selective plasma filtration or bioartificial liver dialysis therapy.
Hospital successfully transplants the first liver dialysis patient in the state